Authors and Disclosures
Julio A. Ramirez2, Frederick J. Angulo, Ruth M. Carrico2, Stephen Furmanek2, Senén Peña Oliva, Joann M. Zamparo, Elisa Gonzalez, Pingping Zhang, Leslie A. Wolf Parrish, Subathra Marimuthu, Michael W. Pride, Sharon Gray, Cátia S. Matos Ferreira3, Forest W. Arnold, Raul E. Istúriz, Nadia Minarovic, Jennifer C. Moïsi and Luis Jodar
University of Louisville, Louisville, Kentucky, USA (J.A. Ramirez, R.M. Carrico, S. Furmanek, S. Peña Oliva, L.A. Wolf Parrish, S. Marimuthu, F.W. Arnold); Pfizer Vaccines, Collegeville, Pennsylvania, USA (F.J. Angulo, J.M. Zamparo, E. Gonzalez, P. Zhang, S. Gray, C.S. Matos Ferreira, R.E. Istúriz, N. Minarovic, J.C. Moïsi, L. Jodar); Pfizer, Pearl River, New York, USA (M.W. Pride)
1Study results were presented at the annual Anaerobe 2022 Congress, July 28–31, 2022, Seattle, Washington, USA.
2Current affiliation: Norton Healthcare, Louisville, Kentucky, USA.
3Current affiliation: AstraZeneca Pharmaceuticals, Wilmington, Delaware, USA.
Address for correspondence
Frederick J. Angulo, Medical Development and Scientific/Clinical Affairs, Pfizer Vaccines, 500 Arcola Rd, Collegeville, PA 19426, USA; email: frederick.j.angulo@pfizer.com
About the Author
Dr. Ramirez is chief scientific officer for the Norton Infectious Diseases Institute at Norton Healthcare in Louisville, KY, and emeritus professor of medicine, Division of Infectious Diseases, University of Louisville. His primary research interests include respiratory tract infections, with a focus on community-acquired pneumonia and emerging respiratory pathogens.
This study was supported by Pfizer Inc., which was involved in the study design, data collection, data analysis, data interpretation, and writing of the article. All authors had full access to the study data and approved the decision to submit for publication. Upon request, and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions and exceptions, Pfizer may also provide access to the related individual de-identified participant data. For more information, see https://www.pfizer.com/science/clinical-trials/trial-data-and-results.
J.A.R. has a grant from Pfizer Inc. to the University ofLouisville Research Foundation for the epidemiologic study.F.J.A., J.M.Z. E.G., P.Z., M.W.P., S.G., R.E.I., J.C.M, and L.J.hold stock and stock options in Pfizer Inc. R.M.C. has grantsor contracts from Pfizer Inc. for C. difficile research andhonoraria from Pfizer Inc. for content development andpresentation regarding C. difficile to professionalorganization. L.A.W.P. and S.M. declare support from PfizerInc. for this study (i.e., kits for performing Quik Chek rapidtests, supplies for aliquoting stool samples, sample forms, and barcoding labels and scanners); contract from Pfizer Inc.to support the project; and receipt of equipment (i.e.,1 biologic safety cabinet, 1 refrigerator, 1 incubator, 1anaerobic chamber, and 1 freezer). C.S.M.F. declaressupport from Pfizer Inc. for this manuscript and stockoptions from AstraZeneca, PLC. F.W.A. declaresinstitutional payment from Pfizer Inc. for this manuscriptand grants or contracts from the US Health Resources andServices Administration for the Ryan White HIV clinic, Janssen for COVID-19 vaccine study, and Gilead for rapidstart antiretroviral therapy study. The other co-authorsdeclare no conflicts of interest.